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Impairment of working memory is one of the most
important deleterious effects of marijuana intoxica-
tion in humans, but its underlying mechanisms are
presently unknown. Here, we demonstrate that
the impairment of spatial working memory (SWM)
and in vivo long-term depression (LTD) of synaptic
strength at hippocampal CA3-CA1 synapses,
induced by an acute exposure of exogenous can-
nabinoids, is fully abolished in conditional mutant
mice lacking type-1 cannabinoid receptors (CB1R)
in brain astroglial cells but is conserved in mice
lacking CB1R in glutamatergic or GABAergic neu-
rons. Blockade of neuronal glutamate N-methyl-
D-aspartate receptors (NMDAR) and of synaptic
trafficking of glutamate a-amino-3-hydroxy-5-
methyl-isoxazole propionic acid receptors (AMPAR)
also abolishes cannabinoid effects on SWM and
LTD induction and expression. We conclude that
the impairment of working memory by marijuana
and cannabinoids is due to the activation of astroglial
CB1R and is associated with astroglia-dependent
hippocampal LTD in vivo.INTRODUCTION
The treatments of pain, nausea, seizures, ischemia, cerebral
trauma and tumors in humans and/or animals are some of the
potential therapeutic applications of derivatives of the plant
Cannabis sativa (marijuana) or synthetic cannabinoids (Lem-
berger, 1980; Robson, 2001; Brooks, 2002; Carlini, 2004; Hall
et al., 2005). However, the potential therapeutic use of cannabis
is limited by important side-effects associated with its use
(Pacher et al., 2006). One of the major side effects of marijuana
intoxication is the impairment of working memory in humans
(Ranganathan and D’Souza, 2006) and animals (Lichtman and
Martin, 1996; Hampson and Deadwyler, 2000; Nava et al.,
2001; Varvel and Lichtman, 2002; Fadda et al., 2004; Hill et al.,
2004; Wise et al., 2009), but the cellular mechanisms of this
effect are presently not known.
Working memory is the ability to transiently hold and process
information for reasoning, comprehension and learning, such
as active thinking. Baddeley introduced a multicomponent
model of human working memory with a central executive
system responsible for information integration and coordination
of two subsystems (Baddeley, 2003). One subsystem, the
phonological loop, stores the sound of language while the
other subsystem, the visuo-spatial sketch pad, stores visual
(e.g., color) and spatial information (i.e., location). This theory
suggests a key role of spatial processing in working memoryCell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc. 1039
performance. Spatial working memory (SWM) in humans
and animals requires online processing of information within
many brain regions including the hippocampus (Hassabis
et al., 2007; Kesner, 2007). The hippocampal excitatory
CA3-CA1 synapses, which connect glutamatergic axons of
CA3 pyramidal neurons, including the ipsilateral Schaffer
collaterals and contralateral commissural fibers, with dendrites
of CA1 pyramidal neurons (Witter and Amaral, 2004), have
been proposed to play a key role in SWM (Rolls and Kesner,
2006).
Multiple forms of memory are likely subserved by activity- or
experience-dependent long-term potentiation (LTP) and depres-
sion (LTD) of synaptic strength (Malenka and Bear, 2004).
Chronic exposure of rats to cannabinoids impairs both LTP
induction at CA3-CA1 synapses and hippocampal-dependent
SWM (Hill et al., 2004), suggesting a link between LTP impair-
ment and SWM impairment. This idea is supported by recent
data that knockout of the AMPAR GluR1 subunit impairs both
LTP induction at CA3-CA1 synapses and SWM (Sanderson
et al., 2008). If LTP at CA3-CA1 synapses indeed contributes
to SWM, LTD at these synapses may play a role in SWM impair-
ment, because LTD could counteract LTP at the same synapses
(Han et al., 2011).
Cannabinoid type-1 receptor (CB1R), one of the most abun-
dant G protein-coupled receptors in the brain (Herkenham
et al., 1990), is found in both GABAergic and glutamatergic
neurons in the hippocampal CA1 region (Herkenham et al.,
1990; Kawamura et al., 2006; Marsicano and Lutz, 2006). Its
main neuronal action is to inhibit presynaptic neurotransmitter
release (Kano et al., 2009; Marsicano and Lutz, 2006). Indeed,
cannabinoids can depress excitatory transmission at CA3-CA1
synapses in brain slices via activation of CB1R (Misner and
Sullivan, 1999; Hajos et al., 2001; Kawamura et al., 2006;
Marsicano and Lutz, 2006; Takahashi and Castillo, 2006; Bajo
et al., 2009; Serpa et al., 2009; Hoffman et al., 2010). Thus,
cannabinoid-induced decrease of excitatory transmission might
be related to SWM impairment. It is entirely unknown, however,
whether cannabinoids are able to induce LTD at CA3-CA1
synapses in living animals and whether such in vivo LTD might
contribute to SWM impairment induced by exogenous cannabi-
noids. In addition to the presence in neurons, CB1R is also found
in hippocampal astroglial cells and its activation, by stimulating
Ca2+-dependent release of glutamate, potentiates synaptic
transmission at CA3-CA1 synapses in brain slices (Navarrete
and Araque, 2010). However, the roles of astroglial CB1R in
the modulation of behavior and synaptic plasticity in living
animals are not known.
In this study, we employed conditional mutagenesis, in vivo
electrophysiology and behavioral tests to study the mechanism
underlying the effect of cannabinoids on hippocampal-depen-
dent SWM. Surprisingly, we found that activation of astroglial
CB1R, but not neuronal CB1R, by exogenous cannabinoids
mediates SWM impairment and LTD induction at CA3-CA1
synapses in vivo. Our data reveal an unanticipated hippocampal
pathway linking astroglial activity, synaptic plasticity and
memory processing, and define the specific mechanisms likely
underlying cannabinoid-induced impairment of SWM in living
animals.1040 Cell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc.RESULTS
Cannabinoids Induce In Vivo LTD at CA3-CA1 Synapses
In vivo recordings of field excitatory postsynaptic potentials
(fEPSP) from CA3-CA1 synapses in anesthetized rats revealed
that an i.p. injection of HU210 (0.05 or 0.1 mg/kg), a potent
synthetic cannabinoid, or D9-tetrahydrocannabinol (THC,
5 mg/kg), the major psychoactive ingredient of marijuana,
decreased fEPSP amplitude to approximately 40% of the
baseline levels (Figures 1A and 1G). Similar results were
obtained after an intra-CA1 infusion of HU210 (Figures S1A
and S1C). In studies hereafter, animals received an i.p. injection
of 0.05 mg/kg of HU210 or 5 mg/kg of THC if not otherwise
stated.
Cannabinoid-induced depression of synaptic transmission at
CA3-CA1 synapses in brain slices is not defined as LTD,
because it is fully reversed by application of CB1R antagonists
10 min after cannabinoid application (Chevaleyre et al., 2006;
Hajos et al., 2001; Kawamura et al., 2006). This indicates the
requirement of a continuous activation of CB1R for cannabinoid
depression of transmission at CA3-CA1 synapses, a character-
istic of transient synaptic depression but not of LTD (Chevaleyre
et al., 2006). However, we observed that the decreased EPSP
amplitude was blocked by injection of the selective CB1R
antagonist AM281 (3 mg/kg, i.p.) (Cui et al., 2001) 10 min before,
but not 10 min after HU210 administration (Figures 1B and 1G),
thus indicating LTD induction by cannabinoid exposure in vivo
(hereafter referred to as CB-LTD). This idea is further supported
by two lines of evidence. First, while synaptic transmission
depression can be transient (in min) or long-lasting (i.e., LTD
lasting > 24 h), a HU210 injection (0.1 mg/kg, i.p.) induced
CB-LTD at CA3-CA1 synapses for > 24 hr in freely moving rats
(Figures 1E and 1G), at a time where the acute effects of the
drug should be decreased. Second, while the maintenance of
late-phase LTD, but not early-phase LTD or transient synaptic
transmission depression, requires new protein synthesis (Kel-
leher et al., 2004), administration of inhibitors of protein transla-
tion (anisomycin, 18 mg/kg, i.p.) (Puighermanal et al., 2009)
or RNA transcription (actinomycin-D, 72 mg/12 ml, i.c.v.)
(Manahan-Vaughan et al., 2000) 2 hr before HU210 injection
selectively reversed the late-phase expression of CB-LTD
(Figures 1C and 1G).
To identify if CB1R expressed in the CA1 area contributes
to CB-LTD at CA3-CA1 synapses, we applied adenoviral
vectors-containing shRNA against CB1R into the CA1 region
4 days prior to HU210 injection. shRNA CB1R specifically
knocked down CA1 expression of CB1R (Figure 1F) and sup-
pressed CB-LTD at CA3-CA1 synapses (Figures 1D and 1G).
Interestingly, the cannabinoid effect seems to be specific for
the CA3-CA1 pathway, because systemic HU210 did not induce
CB-LTD at synapses of the perforant path onto dentate gyrus
neurons (Figures S1B and S1C). Thus, in vivo cannabinoid expo-
sure induces an in vivo LTD at CA3-CA1 synapses.
Neuronal CB1R Is Dispensable for CB-LTD at CA3-CA1
Synapses
Glutamatergic presynaptic membranes of CA3-CA1 synapses
contain CB1R (Kawamura et al., 2006). To test whether CB-LTD
Figure 1. Cannabinoids Induce In Vivo LTD
at CA3-CA1 Synapses
(A–E) Plots of normalized fEPSP slopes in anes-
thetized rats (A–D) or freely moving rats (E) show
that cannabinoid injection at 0 min elicits CA1 LTD
lasting for > 2 hr (A–D) or > 24 hr (E), which is
blocked by AM281 administration 10 min before,
but not 10 min after, HU210 injection (B), or by
intra-CA1 infusion of shRNA CB1R (D), and that
anisomycin (An) and actinomycin-D (AMD)
selectively reverse the late-phase expression of
HU210-elicited LTD (C). Representative fEPSP
traces before (1) and after (2) vehicle or cannabi-
noid injection are shown above each plot.
(F) Graph (top) and immunoblotting photos
(bottom) show a reduction of CA1 CB1R expres-
sion by shRNA CB1R.
(G) Histogram summarizes the average percent
change of fEPSP slope before (1) and after (2)
vehicle or cannabinoid injection as depicted in
panels (A)–(E).
All summary graphs show means ± standard error
of the mean (SEM); n = numbers of animals re-
corded in each group (A–E) or numbers of experi-
ments conducted (F) in each group. *p < 0.01
versus vehicle control, Bonferronni post-hoc test
after one-way ANOVA (A: F3,13 = 56.560, p < 0.01;
B: F3,10 = 39.001, p < 0.01; C: F3,8 = 47.210, p <
0.01; F: F2,6 = 34.990, p < 0.01) or t test.
See also Figure S1.depends on ‘‘glutamatergic’’ CB1R, we examined mutant mice
carrying a selective deletion of the CB1R gene in cortical and
hippocampal glutamatergic principal neurons (Glu-CB1R-KO)
(Monory et al., 2006; Bellocchio et al., 2010). Surprisingly, THC
induced a CB-LTD at CA3-CA1 synapses that was
indistinguishable between wild-type mice and Glu-CB1R-KOCell 148, 1039–105littermates (Figures 2A and 2C). We then
determined the induction of CB-LTD in
mutant mice carrying a selective deletion
of the CB1R gene in brain GABAergic
neurons (GABA-CB1R-KO), including
CA1 GABAergic neurons (Monory et al.,
2006; Bellocchio et al., 2010). Again,
THC induced a CB-LTD at CA3-CA1
synapses that was indistinguishable
between wild-type mice and GABA-
CB1R-KO littermates (Figures 2A and
2C). Thus, CB1R expressed in glutama-
tergic or GABAergic neurons does not
participate in this in vivo form of CB-LTD
in the hippocampal CA1 region.
Astroglial CB1R Mediates CB-LTD
at CA3-CA1 Synapses
CB1R is also functionally expressed in
CA1 astrocytes (Navarrete and Araque,
2008). Therefore, astroglial CB1R might
play a role in CB-LTD at CA3-CA1
synapses. To directly address this issue,we generated tamoxifen-inducible conditional mutant mice
specifically lacking CB1R expression in astrocytes. ‘‘Floxed’’
CB1R mutant mice (Marsicano et al., 2003) were crossed with
transgenic mice expressing the inducible version of the Cre
recombinase CreERT2 under the control of the promoter of
the human glial fibrillary acidic protein (GFAP-CreERT2 mice,0, March 2, 2012 ª2012 Elsevier Inc. 1041
Figure 2. Cannabinoids Elicit CA1 LTD via Astroglial CB1R but Not Neuronal CB1R
(A and B) Plots of normalized fEPSP slopes in anesthetized mice show that THC injection at 0 min elicits CA1 LTD in wild-type (WT), Glu-CB1R-KO and GABA-
CB1R-KO mice (A), but not in GFAP-CB1R-KO mice (B). Representative fEPSP traces before (1) and after (2) treatment are shown above each plot.
(C) Histogram summarizes the average percent changes of fEPSP slope before (1) and after (2) treatment.
(D and E) Histograms summarize the percentage of CB1R-labeled astrocytes and axons/terminals in GFAP-CB1R-WTmice, GFAP-CB1R-KOmice andCB1R-KO
mice.
(F) Electron microscopic images show a high density of CB1R immunopositive silver grains (small arrows) in axons/terminals of both tamoxifen-treated GFAP-
CB1R-WT and GFAP-CB1R-KO mice, and a low density of silver grains (large arrow) in DAB-stained astrocytes (arrowheads) of GFAP-CB1R-WT mice but not of
GFAP-CB1R-KO littermates. The scale bar represents 500 nm.
(G) An electron microscopic image shows an absence of CB1R immunopositive silver grains in astrocytes stained with peroxidase/DAB and axons. The scale bar
represents 500 nm.
All summary graphs showmeans ±SEM; n = numbers of animals recorded (A, B) or numbers of positive immunoreactive profiles counted (D, E) in each group. *p <
0.01 versus control, Bonferronni post-hoc test after one-way ANOVA (A: F2,6 = 68.603, p = 0.884; B: F2,8 = 42.009, p < 0.01) or square Chi test (D).
1042 Cell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc.
Figure 3. Cannabinoids Induce NMDAR-
Dependent LTD at CA3-CA1 Synapses
(A–E) Plots of normalized fEPSP slopes in anes-
thetized rats are presented with representative
fEPSP traces (above plots) before (1) and after (2)
vehicle or drug injection. An i.c.v. injection of TBOA
induces LTD (A). E4CPG, but not vehicle, blocks
LTD induced by DHPG injection at 0 min (B)
without significant effects on LTD induced by
HU210 (C). Intra-CA1 application of AP-5
suppresses HU210-induced LTD (D). Systemic
administration of Ro25-6981 and ifenprodil,
but not NVP-AAM077, prevents HU210-induced
LTD (E).
(F) Histogram summarizes the average percent
change of fEPSP slope before (1) and after (2) drug
or vehicle injection.
All summary graphs show means ± SEM; n =
numbers of animals recorded in each group.
*p < 0.01 versus control, Bonferronni post-hoc test
after one-way ANOVA (B: F2,7 = 36.090, p < 0.01;
E: F3,10 = 40.409, p < 0.01) or t test.Hirrlinger et al., 2006) to eventually obtain the GFAP-CB1R-KO
mouse line. As compared to tamoxifen-treated wild-type
littermate controls (GFAP-CB1R-WT), GFAP-CB1R-KO mice
displayed a 79% reduction (p < 0.01) in the number of CA1
astrocytes labeled with a CB1R antibody (Figures 2D and 2F),
whereas only background levels were observed in constitutive
CB1R-KO mice (Figures 2E and 2G). Conversely, no difference
(p = 0.2293) was observed between GFAP-CB1R-WT and
GFAP-CB1R-KO mice in the number of CB1R-labeled CA1
neuronal axons/terminals (Figures 2D and 2F). THC elicited
CB-LTD at CA3-CA1 synapses in tamoxifen-treated wild-type
mice but not in GFAP-CB1R-KO mutant littermates (Figures 2B
and 2C). Therefore, cannabinoid exposure in vivo elicits
CB-LTD at CA3-CA1 synapses through CB1R expressed in
astroglial cells.Cell 148, 1039–105Mechanisms of CB-LTD at CA3-CA1
Synapses
Cannabinoids are able to activate hippo-
campal astroglial CB1R to increase
extracellular glutamate levels (Navarrete
and Araque, 2008). If a similar mechanism
is involved in CB-LTD, LTD should
be induced by the glutamate-uptake
inhibitor DL-threo-b-benzyloxyaspartate
(TBOA). Indeed, an i.c.v. injection of
TBOA (10 nmol) (Wong et al., 2007)
induced in vivo LTD at CA3-CA1 syn-
apses (Figures 3A and 3F). If increased
extracellular levels of glutamate induce
LTD at CA3-CA1 synapse, postsyn-
aptic metabotropic glutamate receptor
(mGluR) may be responsible for this LTD
induction, because postsynaptic mGluR
activation produces LTD (Chevaleyre
et al., 2006; Lovinger, 2008). However,
the selective group I/group II mGluRantagonist ethyl-4-carboxyphenylglycine (E4CPG, 35 nM/
3.5 ml, i.c.v.) completely blocked in vivo LTD induced by the
group I mGluR agonist dihydroxyphenylglycine (DHPG,
100 nM/5 ml, i.c.v.), but did not alter CB-LTD (Figures 3B, 3C,
and 3F). Surprisingly, CB-LTD was fully blocked by the selective
NMDAR antagonist AP-5 (50 mM, intra-CA1 iontophoretic
ejection at 20 nA for 10 min) (Maalouf et al., 1998) (Figures
3D and 3F), and by the NR2B-preferring NMDAR antagonists
Ro25-6981 (6 mg/kg, i.p.) (Fox et al., 2006) and ifenprodil
(5 mg/kg, i.p.) (Higgins et al., 2005) (Figures 3E and 3F). How-
ever, the NR2A-preferring NMDAR antagonist NVP-AAM077
(1.2 mg/kg, i.p.) (Fox et al., 2006) did not alter CB-LTD in the
same conditions (Figures 3E and 3F). Thus, in vivo cannabinoid
exposure induces CB-LTD at CA3-CA1 synapses via activation
of NR2B-containing NMDAR.0, March 2, 2012 ª2012 Elsevier Inc. 1043
Figure 4. Cannabinoids Induce AMPAR
Endocytosis-Dependent Expression of CA1
LTD
(A and B) Graphs and immunoblotting (bottom
photos) show a decrease of GluR1 and GluR2 at
the synaptic surface of CA1 neurons after HU210
injection, which is blocked by pretreatment with
Tat-GluR2 but not Tat-GluR2S.
(C) Plot of normalized fEPSP slopes in anes-
thetized rats shows that injection of Tat-GluR2, but
not Tat-GluR2S, 2 hr before HU210 injection at
0 min blocks HU210-induced LTD. Representative
fEPSP traces before (1) and after (2) HU210
injection are shown above the plot.
(D) Histogram summarizes the average percent
change of fEPSP slope before (1) and after (2)
HU210 injection (C) or Tat-GluR2 injection (E).
(E) Plot of normalized slopes of fEPSPs in anes-
thetized rats shows both naive rats and rats
receiving Tat-GluR2 injection at 0 min display
similar fEPSPs at CA3-CA1 synapses for 4 hr.
Representative fEPSP traces recorded during
10–0 min (1) and 230–240 min (2) are shown
below the slopes.
All summary graphs show means ± SEM; n =
numbers of experiments conducted (A and B) or
numbers of animals recorded (C and E) in each
group. *p < 0.05 versus control, t test.The expression of NMDAR-mediated LTD requires facilitated
endocytosis of postsynaptic AMPAR (Collingridge et al., 2010).
AMPAR in CA1 pyramidal cells consists of 81% of GluR1/
GluR2 at synaptic membranes (Lu et al., 2009). The surface
levels of GluR1/GluR2 in synaptosomes isolated from the CA1
region significantly decreased after HU210 injection (Figure 4A),
suggesting endocytosis of AMPAR in postsynaptic CA1 pyra-
midal cells following cannabinoid exposure in vivo. The adminis-
tration of the brain-penetrating version of a peptide able to
block GluR2 endocytosis (‘‘Tat-GluR2’’ peptide, 1.5 mmol/kg,
i.p.), but not of its scrambled analog (Tat-GluR2S) (Brebner
et al., 2005; Wong et al., 2007; Collingridge et al., 2010), specif-
ically blocked both HU210-induced GluR1/GluR2 endocytosis1044 Cell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc.(Figure 4B) in the CA1 and CB-LTD (Fig-
ures 4C and 4D). Tat-GluR2 (1.5 mmol/kg,
i.p.) did not significantly change the
fEPSP amplitude at CA3-CA1 synapses
for 4 hr after injection (Figures 4D and
4E). Altogether, these data strongly sug-
gest that postsynaptic endocytosis of
GluR1/GluR2 mediates the expression of
CB-LTD at CA3-CA1 synapses.
Cannabinoid Impairment of
Working Memory Shares the Same
Mechanisms of CB-LTD
CB-LTD is characterized by (1) activa-
tion of astroglial CB1R, (2) activation
of NMDAR, and (3) internalization of
AMPAR. These mechanisms were as-sessed in different behavioral models of cannabinoid impair-
ment of spatial working memory (SWM).
The role of astroglial CB1R in cannabinoid impairment of
SWM was assessed by examining SWM performance of
tamoxifen-treated GFAP-CB1R-WT and GFAP-CB1R-KO litter-
mates with a delayed-matching-to place (DMTP) version of the
Morris water maze test (Steele and Morris, 1999). No significant
differences were observed between wild-type and mutant
littermates during training (Figure S2A). In agreement with a
previous study (Varvel and Lichtman, 2002), THC impaired
SWM performance in GFAP-CB1R-WT mice, as evidenced by
a significant decrease of both latency saving ratios (Figure 5A)
and path saving ratios (Figure 5B). In contrast, THC did not
Figure 5. Astroglial CB1R, NMDAR, and AMPAR
Mediate Cannabinoid Impairment of SWM
(A–D) Mouse DMTP version of the Morris water maze test.
THC reduces both latency saving ratio (A) and path saving
ratio (B) in wild-type mice (A – D) and GABA-CB1R-KO
littermates but not in GFAP-CB1R-KO littermates. While
vehicle-treated Glu-CB1R-KO littermates show a signifi-
cant decrease of both latency saving ratio and path saving
ratio relative to vehicle-treated wild-type mice (C and D),
THC reduces latency saving ratio (C) but not path saving
ratio (D) in Glu-CB1R-KO littermates.
(E and F) Rat DMTP version of the Morris water maze test.
HU210 reduces both path saving ratio (E) and latency
saving ratio (F), which are prevented by i.p. pretreatment
with Ro25-6981 or Tat-GluR2, while neither Ro25-6981
nor Tat-GluR2 significantly affects the ratio in the absence
of HU210.
All summary graphs show means ± SEM; n = numbers of
animals tested in each group. *p < 0.05 versus control,
Bonferronni post-hoc test after repeated-measure two-
way ANOVA ([A] F1,22 = 13.010, p < 0.01; [B] F1,22 = 7.999,
p < 0.01; [C] treatment: F1,30 = 37.28, p < 0.001; genotype x
treatment F2,30 = 2.92, p > 0.05; [D] treatment: F1,30 =
30.01, p < 0.001; genotype x treatment F2,30 = 4.25,
p < 0.05) or one-way ANOVA ([E] F5,36 = 19.307, p < 0.01;
[F] F5,36 = 13.110, p < 0.01).
See also Figures S2 and S5.produce significant effects on GFAP-CB1R-KO littermates
(Figures 5A and 5B). While Glu-CB1R-KO littermates showed
a significant impairment of the acquisition of SWM (Figure S2B)
and subsequent poor performance of SWM in comparison
with wild-type mice (Figures 5C and 5D), THC impaired SWM
performance (Figure 5C). Both GABA-CB1R-KO littermates and
control wild-type mice showed similar acquisition of SWM
(Figure S2B), and THC impaired SWM performance (Figures
5C and 5D). THC treatment did not alter swim speed of GFAP-
CB1R-WT and GFAP-CB1R-KO mice (Figure S2C), but slightly
decreased this parameter in Glu- and GABA-CB1R-KO mice
and WT littermates (Figure S2D). However, this slight effect
was equal for all genotypes (Figure S2D) and was equally distrib-
uted among different trials (data not shown), thereby excluding
its involvement in the altered SWM performance of the mice.
Thus, CB1R in glutamatergic neurons, but not CB1R in
GABAergic neurons or astroglial cells, is necessary for mice to
acquire SWM. Notably, however, astroglial CB1R, but not gluta-
matergic or GABAergic neuronal CB1R, is necessary to produce
the detrimental effects of THC on SWM.
To test if NMDAR activation plays a role in cannabinoid im-
pairment of SWM, rats were tested in a T-maze using a delayed
nonmatching to sample protocol (DNMTST) (Kelsey and
Vargas, 1993). After 6 daily training sessions to ensure that
the task was mastered (>80% correct choices, Figure S3A),
rats received 2 daily test sessions 30 min after injection of
HU210 or vehicle. Ten min before HU210 injection, rats wereCell 148, 103pretreated with Ro25-6981 or ifenprodil, two
NR2B-preferring NMDAR antagonists, or NVP-
AAM077, a NR2A-prefering NMDAR antag-
onist. The results show that NR2B- but notNR2A-preferring NMDAR antagonists abrogated HU210-in-
duced impairment of SWM performance (Figure 6A). Thus,
activation of NR2B-containing NMDAR is necessary for the
cannabinoid-induced impairment of SWM.
The effects of the blockade of AMPAR internalization on
cannabinoid-induced SWM impairment was also tested in the
DNMTST paradigm. After 6 daily training sessions (Figure S3B),
rats received Tat-GluR2 or Tat-GluR2S (1.5 mmol/kg, i.p.) (Breb-
ner et al., 2005; Wong et al., 2007) 2 hr before HU210 injection
on each of the two testing days. Tat-GluR2, but not Tat-GluR2S,
abolished HU210 impairment of SWM performance (Figure 6B).
To determine the specific role of the CA1 region, after 6 daily
training sessions (Figure S3C), Tat-GluR2 or Tat-GluR2S was
infused bilaterally within the dorsal CA1 region (15 pmol/per
injection) (Brebner et al., 2005; Wong et al., 2007) (Figure 6C)
60 min before each HU210 injection on each testing day. Intra-
CA1 infusion of Tat-GluR2, but not Tat-GluR2S, blocked HU210
impairment of SWM performance (Figure 6D). Neither systemic
nor intra-CA1 administration of Tat-GluR2 significantly affected
basal locomotor activity, anxiety level or motor balance (Figures
S4A–S4E). Thus, AMPAR internalization in the CA1 hippocampal
region is necessary for cannabinoid-induced alteration of SWM.
If intra-CA1 infusion of HU210 is able to induce CB-LTD
at CA3-CA1 synapses (Figures S1A and S1C), a bilateral
intra-CA1 infusion of HU210 should impair SWM. As expected,
after six daily training sessions (Figure S3D), HU210 (0.1 mg/
0.5 ml/side) impaired rat SWM performance (Figure 6E).9–1050, March 2, 2012 ª2012 Elsevier Inc. 1045
Figure 6. NMDAR and AMPAR Mediate Cannabinoid Impairment of SWM
(A) Rat DNMTS T-maze. HU210 suppresses SWM performances, which is prevented by i.p. pretreatment with Ro25-6981 and ifenprodil, but not with NVP-
AAM077.
(B and D) Rat DNMTS T-maze. Systemic (B) and intra-CA1 administration (D) of Tat-GluR2, but not Tat-GluR2S, blocks HU210 impairment of SWM performance.
(C) Photograph (left) shows location of an intra-CA1 cannula, and histograms (right) show reconstructions of histology sections illustrating CA1 injection sites of
Tat-GluR2 (solid circle) and Tat-GluR2S (open circle).
(E) Intra-CA1 injection of HU210, but not vehicle, impairs SWM performance.
All summary graphs showmeans ± SEM; n = numbers of animals tested in each group. *p < 0.01 versus control, Bonferronni post-hoc test after one-way ANOVA
(A: F5,36 = 59.070, p < 0.01; B: F3,28 = 54.220, p < 0.01; D: F3,32 = 41.562, p < 0.01; E: F1,12 = 36.090, p < 0.01).
See also Figures S3 and S4.Finally, we tested if the results obtained with the DNMTST
paradigm were reproducible with the DMTP water maze para-
digm. One day after five daily training sessions to establish the
baseline levels of SWM (Figure S5A), rats received a test session
of four trials. HU210 treatment before the test session impaired
SWM performance, which was blocked by pretreatment with
Ro25-6981 or Tat-GluR2 (Figures 5E and 5F). Neither Ro25-
6981 nor Tat-GluR2 administration alone significantly changed
saving ratios (Figures 5E and 5F), suggesting that neither
NR2B-preferring NMDAR antagonists nor Tat-GluR2 interferes
with basal SWM performance. Swim speeds during the SWM
task were not influenced by different treatments (Figure S5B).
Thus, cannabinoid administration alters SWM performance in
different behavioral tasks through the same mechanisms.
Altogether, these data show that the same mechanisms
underlying CB-LTD at hippocampal CA3-CA1 synapses (activa-
tion of astroglial CB1R, activation of NMDAR and removal of
AMPAR from the synaptic surface) also mediate cannabinoid-
induced alterations of hippocampal-dependent SWM.
DISCUSSION
This study shows that one of themost common effects of canna-
binoid intoxication in humans and animals, the impairment of1046 Cell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc.SWM, is due to activation of astroglial CB1R. Furthermore,
a novel form of cannabinoid-induced long-term synaptic plas-
ticity in the hippocampus appears to mechanistically underlie
this effect of cannabinoids in vivo. Our results are consistent
with a scenario (Figure 7), in which cannabinoid exposure in vivo
activates astroglial CB1R to increase ambient glutamate, which
in turn activates NR2B-containing NMDAR to trigger AMPAR
internalization at CA3-CA1 synapses. These events ultimately
induce CB-LTD at these synapses, altering the function of hippo-
campal circuits that likely become unable to process SWM
(Figure 7).
Early studies demonstrate that CB1R is expressed at high
levels by neurons throughout the whole brain (Herkenham
et al., 1990; Matsuda et al., 1993; Tsou et al., 1998). More recent
studies show that CB1R is more abundant in GABAergic inter-
neurons than in glutamatergic principal neurons (Kawamura
et al., 2006). In the hippocampal CA1 area, CB1R density on
GABAergic presynaptic membranes is at least 10–20 times
higher than that on glutamatergic presynaptic membranes
(Kawamura et al., 2006; Bellocchio et al., 2010). Cannabinoid
depression of in vitro excitatory or inhibitory synaptic transmis-
sion has been consistently shown to require CB1R in either
glutamatergic or GABAergic presynaptic terminals, respectively
(Misner and Sullivan, 1999; Chevaleyre et al., 2006; Kawamura
Figure 7. Proposed Model for In Vivo LTD Production at CA3-CA1
Synapses and Subsequent Working Memory Impairment
CB1R exists in CA1 astrocytes (Figures 2D–2G) and presynaptic membranes
with 10- to 20-fold of CB1R density in GABAergic membranes than gluta-
matergic membranes (Kawamura et al., 2006). GABAergic and glutamatergic
terminals containing CB1R synapse with dendrites and spines of CA1 pyra-
midal cells, respectively (Kawamura et al., 2006). In vitro activation of
presynaptic CB1R by cannabinoids reduces the release of glutamate and
GABA from glutamatergic and GABAergic membranes, respectively.
However, cannabinoid exposure in vivo sequentially activates astroglial CB1R
and postsynaptic NR2B-containing NMDAR, which elicits AMPAR endocy-
tosis-mediated expression of in vivo LTD at CA3-CA1 synapses, resulting in
working memory impairment.et al., 2006; Takahashi and Castillo, 2006; Navarrete and
Araque, 2008, 2010; Bajo et al., 2009). Indeed, cannabinoids
fail to reduce excitatory or inhibitory synaptic transmission in
hippocampal slices of conditional mutant mice lacking CB1R
expression in either glutamatergic or GABAergic hippocampal
neurons, respectively (Domenici et al., 2006; Monory et al.,
2006). Unexpectedly, we observed here that in vivo exposure
to exogenous cannabinoids induced full CB-LTD at excitatory
CA3-CA1 synapses in both wild-type mice and mutant litter-
mates lacking CB1R in either CA1 glutamatergic or GABAergic
neurons. These data do not support an involvement of glutama-
tergic or GABAergic CB1R in in vivo CB-LTD at CA3-CA1
synapses.
The presence of CB1R has also been suggested in brain
astrocytes (Moldrich and Wenger, 2000; Rodriguez et al., 2001;
Salio et al., 2002), but the extremely low levels of CB1R expres-
sion in this cell population did not allow reaching the same
conclusive evidence of functional data (Navarrete and Araque,
2008, 2010). The use of double immunostaining applied to
wild-type and conditional or constitutive CB1R mutant mice al-
lowed us to provide conclusive electron microscopic evidencethat CB1R is expressed and quantifiable in hippocampal astro-
cytes. We have further showed here that in vivo CB-LTD at
CA3-CA1 synapses was not detectable in tamoxifen-inducible
conditional mutant mice specifically lacking CB1R expression
in astrocytes (i.e., GFAP-CB1R-KO littermates). Our results
strongly suggest a requirement of astroglial CB1R for CB-LTD
at CA3-CA1 synapses in living animals.
However, we also found that THC exposure in vivo did not
significantly alter basal synaptic transmission in GFAP-CB1R-
KO littermates. These data, together with the finding that the
density of presynaptic CB1R at CA3-CA1 synapses is just above
the background levels (Kawamura et al., 2006), suggest a negli-
gible role of presynaptic CB1R in excitatory transmission in vivo
at CA3-CA1 synapses in response to exogenous cannabinoid
exposure. Thus, in vitro cannabinoid application decreases
excitatory synaptic transmission at CA3-CA1 synapses via acti-
vation of ‘‘glutamatergic’’ CB1R, whereas in vivo cannabinoid
administration induces CB-LTD via astroglial CB1R without
significant effects on presynaptic CB1R. The exact reason for
this apparent mechanistic discrepancy between in vitro and
in vivo effects of cannabinoids on synaptic transmission and
plasticity is not known. Nevertheless, it is important to note
that intact astroglial networks play prominent roles in brain
functioning (Giaume et al., 2010). Indeed, astrocytes are more
associated in networks than neurons due to the presence
of high levels of gap junctions and direct intercellullar com-
munications (Giaume et al., 2010). It is therefore possible that
the unavoidable disruption of these networks by slicing proce-
dures might alter the impact of astroglial CB1R signaling
in vitro. Meanwhile, slicing procedures might also upregulate
the number or function of presynaptic CB1R, leading to
a decrease of glutamatergic transmission upon its activation
by exogenous cannabinoids. This idea is supported by the
evidence that although CB1R density is at least 10-20 times
higher on inhibitory than excitatory terminals in the CA1 region
(Kawamura et al., 2006; Bellocchio et al., 2010), application of
a saturating concentration of WIN22,212-2 (2 mM) to hippo-
campal slices produced similar depression (50%) of EPSC
(Kawamura et al., 2006) and IPSC (Hajos and Freund, 2002) in
the CA1 area. Because brain slice preparations are extensively
used for studying alterations of synaptic strength following
in vitro application of other drugs of abuse, it is worthwhile to
explore whether astrocytes play a key role in the in vivo effects
of these drugs of abuse that are different from their in vitro
effects.
Recent studies with brain slices show that endocannabinoids
activate CA1 astroglial CB1R to increase extracellular glutamate
levels, which in turn activate presynaptic mGluR to induce LTP at
CA3-CA1 synapses (Navarrete and Araque, 2008, 2010).
However, we show here that cannabinoids activate astroglial
cells to induce in vivo LTD at CA3-CA1 synapses. It is currently
unknown why activation of astroglial CB1R by in vitro endocan-
nabinoid and in vivo cannabinoid induces, respectively, in vitro
LTP and in vivo LTD at CA3-CA1 synapses. It is possible that
activation of astroglial CB1R in brain slices with disrupted astro-
glial networksmight produce lower levels of interstitial glutamate
than those produced in living animals with intact astroglial
networks, which then activate presynaptic mGluR in vitro andCell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc. 1047
postsynaptic NMDAR in vivo, respectively, to induce in vitro LTP
and in vivo LTD at CA3-CA1 synapses.
This study confirmed the consistent finding that HU210 and
THC impair SWM in rodents (Lichtman and Martin, 1996; Hamp-
son and Deadwyler, 2000; Nava et al., 2001; Varvel and Licht-
man, 2002; Fadda et al., 2004; Hill et al., 2004; Wise et al.,
2009). Although a recent study claimed the inability of systemic
HU210 injection to impair SWM tested with the DMTP water
maze paradigm (Robinson et al., 2007), this study failed to use
the ‘saving ratio’ analysis as we and others (Varvel and Lichtman,
2002) have successfully used to identify the detrimental effects
of HU210 and THC on rodent SWM performance.
While glutamatergic axonal CB1R is in part responsible for
cannabinoid-elicited locomotor suppression, catalepsy and
hypothermia (Monory et al., 2007), hippocampal GABAergic
axonal CB1R likely plays a key role in cannabinoid impairment
of long-term memory (Puighermanal et al., 2009). Our data using
GABA-CB1R-KO mice clearly show that ‘‘GABAergic’’ CB1R is
fully dispensable both for basal performance of the SWM task
and, most importantly in this context, for the acute effect of
exogenous cannabinoids. By showing that Glu-CB1R-KO mice
are impaired in basal performance of the SWM task, our data
suggest that CB1R expressed in cortical glutamatergic neurons
participates in the endogenous control of SWM. This control
might be exerted acutely by endogenous mobilization of
endocannabinoids during the task or can also be due to devel-
opmental effects of CB1R deletion in this cell population
(Mulder et al., 2008). However, exogenous THC treatment of
Glu-CB1R-KO mice is still able to further reduce their poor
performance, strongly suggesting the dispensable role of ‘‘gluta-
matergic’’ CB1R in the acute effects of exogenous cannabinoids
on SWM performance.
Conversely, by showing that GFAP-CB1R-KO mice display
normal learning of SWM, but totally fail to respond to THC, the
present study provides striking evidence for the necessary role
of astroglial CB1R in SWM impairment induced by exogenous
cannabinoids.
Cannabinoid-induced LTD and impairment of SWM share not
only the dependency on astroglial CB1R but also a whole
series of well-defined molecular mechanisms. Thus, the phar-
macological blockade of NR2B-containing NMDAR, but not
NR2A-containing NMDAR, prevented both CB-LTD at CA3-
CA1 synapses and cannabinoid impairment of SWM. Moreover,
the Tat-GluR2 peptide can selectively block the facilitated
endocytosis of AMPAR (Collingridge et al., 2010), the final step
of the expression of NMDAR-dependent LTD (Collingridge
et al., 2010), without significant effects on LTP induction or basal
synaptic transmission (Collingridge et al., 2010). Both systemic
and intra-CA1 application of the Tat-GluR2 peptide not only
disrupted the expression of CB-LTD at CA3-CA1 synapses but
also cannabinoid impairment of SWM, as assessed with both
the DMTP version of the Morris water maze test and the DNMTS
T-maze test.
Collectively, at least three key molecular mechanisms are
shared by CB-LTD and cannabinoid-induced impairment of
SWM: (1) activation of astroglial CB1R by the exogenous canna-
binoid; (2) increase of local glutamate and activation of NR2B-
containing NMDAR; (3) endocytosis of AMPAR (Figure 7). These1048 Cell 148, 1039–1050, March 2, 2012 ª2012 Elsevier Inc.findings strongly suggest a causative role of CB-LTD at CA3-
CA1 synapses in cannabinoid-induced impairment of SWM
and reveal novel mechanistic views of the role of astrocytes in
learning and memory processes and of the memory-disruptive
effects of marijuana intoxication.
EXPERIMENTAL PROCEDURES
Generation of Mutant Mice
Constitutive CB1R-KO mice and conditional Glu-CB1R-KO and GABA-CB1R-
KOmice were generated and genotyped as described (Marsicano et al., 2002;
Monory et al., 2006). GFAP-CB1R-KOmice were generated using the Cre/loxP
system. Mice carrying the ‘‘floxed’’ CB1R gene (CB1
f/f) (Marsicano et al., 2003)
were crossed with GFAP-CreERT2 mice (Hirrlinger et al., 2006), using a three-
step backcrossing procedure to obtain CB1R
f/f;GFAP-CreERT2 and CB1R
f/f litter-
mates, called GFAP-CB1R-KO and GFAP-CB1R-WT, respectively.
Immunohistochemistry for Electron Microscopy
Animals were transcardially fixed with 0.1% glutaraldehyde, 4% formaldehyde
and 0.2% picric acid or with 2% formaldehyde and 8% picric acid. Hippo-
campal vibrosections were cut for double preembedding staining of CB1R
and GFAP with silver-intensified immunogold method and immunoperoxidase
method. Tissue preparations were photographed for quantification of positive
immunoreactive profiles. Detailed procedures are described in the extended
methods in the SOMs.
Adenovirus Preparation and Administration
Recombinant adenoviruses were prepared as described (Liu et al., 2010). After
intra-CA1 infusion of adenoviral vectors (1010 plaque-forming units/ml/injec-
tion), the CA1 area surrounding the injection tract was dissected 4 days later
for quantification of CB1R protein with procedures as described (Ji et al.,
2006; Liu et al., 2010).
Synaptosomal Surface AMPAR Measurement
Biotinylation experiments for the CA1 area on hippocampal slices were per-
formed as described (Kim et al., 2007). Protein fractions were transferred
onto nitrocellulose membranes, which were probed with primary antibodies
to GluR1 (1:250, Millipore, Billerica, MA) or GluR2 (1:500, Millipore, Billerica,
MA) overnight at 4C. Bands were analyzed by densitometry, and receptor
ratios for AMPAR subunits were determined by dividing the surface intensity
by the total intensity.
Electrophysiology Analysis
Under anesthesia, rats or mice received implantation of stimulating and
recording electrodes into the CA1 region. fEPSPs were evoked by applying
single pulses of stimulation at 0.067 Hz. Stimulus pulse intensities were 20-
60 nA with a duration of 500 ms. Spike2 software was utilized to record data.
Procedures for fEPSP recordings from freely moving rats were generally
similar to those from anaesthetized rats with the exception of allowing rats
to recover for 2 weeks after surgery for electrode implantation. Detailed
procedures are described in the extended methods in the SOMs.
Behavioral Tests
Water Maze Test
Micewere tested in a DMTP version of theMorris water maze paradigm (Steele
and Morris, 1999). Briefly, after a habituation session of 3 trials without spatial
cues, mice received daily training sessions of 4 trials each with the maximal
escape latency of 60 s, and 30 min before each of the sessions 6 through
12 and before the 13th session, mice were treated with vehicle and THC
(5mg/kg, i.p.), respectively. Performances of individual SWMswere calculated
using the ‘‘saving ratio’’ procedure (Varvel and Lichtman, 2002) and calculated
as follows: path saving ratio = (path-length trial1 - path-length trial4) / (path-
length trial1 + path-length trial4); and latency saving ratio = (escape latency
trial1 - escape latency trial4) / (escape latency trial1 + escape latency trial4).
Procedures for rat water maze test were generally similar to mouse water
maze test with the exception that rats received 5 daily sessions of SWM
training 1 day before a testing session of 4 trials with the maximal escape
latency of 90 s. Detailed procedures are described in the extended methods
in the SOMs.
Other Behavioral Tests
Rats were examined with the DNMTS T-maze test (Kelsey and Vargas, 1993),
locomotor activity test (Ji et al., 2006), elevated-plus-maze test (Ji et al., 2006)
and motor balance tests (Ji et al., 2006).
Statistical Analysis
Results were reported asmean ±SEM. Statistical analysis of the data was per-
formed using a student t test, square Chi test, one-way ANOVA, or one-way or
two-way ANOVA for repeated-measures, followed by Bonferronni post-hoc
test. Statistical significance was set at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2012.01.037.
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